Supriya says LATAM curbs defer high-margin sales 4-5 months

Supriya Lifesciences said post-first-quarter regulatory changes in Latin America (LATAM) have deferred firm orders for high-margin products by at least four to five months, leading management to guide for a 25% full-year earnings before interest, tax, depreciation and amortisation (EBITDA) margin while retaining its Rs 1,000 crore revenue target.

Why have Supriya's LATAM sales been deferred by four to five months?

Supriya said regulatory requirements changed after the first quarter in several LATAM markets without prior notice to either the business or its customers. The changes affect high-volume, high-margin products whose customers now need individual import permits before shipments can resume, and management said securing those permits will take at least four to five months.

The interruption is primarily a timing issue rather than stated demand destruction, according to Supriya. It retains purchase orders and visibility of firm customer orders, but cannot supply the affected products until customers receive the new permits. Some customers could obtain approval earlier, but management said the broader four-to-five-month process makes it difficult to capture the full sales effect during the current financial year.

The affected products carried higher prices and margins in LATAM because it is a regulatory-focused market, management said. Their delayed volumes therefore affect both revenue and profitability more than lower-margin sales elsewhere. Supriya said the regulatory change occurred after it had maintained its earlier margin outlook based on purchase orders already in hand.

LATAM had increased from about 10% to 21% of Supriya's sales historically before declining to 12% in the quarter discussed on the call. Management described the region as a growth market and said larger volumes could return once the permit process normalises, but it did not give a date or rupee value for a complete recovery.

Why did Supriya lower its EBITDA margin guidance to 25%?

Supriya lowered its full-year EBITDA margin guidance to 25% because delayed LATAM sales, Ambernath operating costs, and higher raw-material and solvent prices occurred together. Management said the EBITDA margin was 22% at the time of the call, compared with a typical range of 34% to 35%.

The LATAM disruption was one factor rather than the sole reason for the revision. Management did not accept an analyst's suggestion that the full margin reduction could be assigned to Latin America. It said the high-margin LATAM product deferral changed the market and product mix, while Ambernath costs and input-price pressure continued separately.

Ambernath is expected to incur almost Rs 60 crore of expense for the full year while generating revenue closer to zero during the current financial year, management said. The European Union (EU) audit had been expected earlier, but was scheduled for the following week in the third quarter, removing an anticipated quarter of revenue generation from the site.

Raw-material, key starting material and solvent prices have also increased further since the first quarter, Supriya said. It has communicated higher prices to customers under a purchase-order model, but existing contracts for large regulated-market customers must still be served at prior prices. Management expects the fuller effect of revised pricing to emerge only in the next two quarters.

Can Supriya still deliver Rs 1,000 crore of revenue?

Supriya said it remains confident of meeting its Rs 1,000 crore full-year revenue guidance despite the LATAM deferral. Revenue in the first half was Rs 396 crore, meaning the second half would need to contribute close to Rs 600 crore to reach the target, as an analyst noted during the call.

Management based that confidence on inventory, its order book and products scaling in semi-regulated markets. It specifically cited anesthetic products, cardiovascular products and advanced intermediates as sales sources that can offset delayed Latin American shipments. Management cautioned, however, that these sales do not replace the same high-margin product and market mix.

Supriya said its existing baseline business continues to grow in regulated markets. Management maintained a longer-term aim of revenue growth above 20% over the next three to four years, supported by baseline sales, new launches and contract manufacturing opportunities in active pharmaceutical ingredients (APIs) and finished formulations.

Newly launched products have shown traction in domestic and semi-regulated markets, Supriya said. Its anesthetic product has received a Certificate of Suitability (CEP) for Europe, while management said United States drug master file approval was expected soon. A large contract manufacturing opportunity involving the anesthetic project was described as close to signing but had not been announced.

What must happen for Supriya's margins and LATAM sales to recover?

Supriya said the recovery path depends on customer import permits in LATAM, pass-through of higher input costs and regulatory approvals for Ambernath. Management retained its 25% full-year EBITDA margin guidance because delayed high-margin LATAM sales could continue to weigh on the next two quarters.

If permits are issued, Supriya can supply the firm orders already on hand, but management did not predict the timing of approvals for individual customers. It said margins could improve if conditions streamline, but kept the 25% guidance because the customer licensing timeline is longer than initially anticipated.

Ambernath must first receive approvals and then build commercial sales to cover its cost base. Management said the facility needs Rs 160 crore to Rs 200 crore of revenue to reach break-even, against an annual expense run rate of about Rs 60 crore. It estimated that reaching a meaningful revenue level could take around one to one-and-a-half years after positive EU audit news because product registrations are also needed.

A potential larger contract would initially be API-led because Supriya already has the required approvals for that part of the business. Finished-formulation production would follow only after Ambernath receives approvals across relevant markets. Management said the site has injection, tablet, capsule and liquid-inhalation lines and is designed eventually to generate at least Rs 450 crore to Rs 500 crore of revenue.

Conclusion

Supriya's 25% EBITDA margin guidance reflects a combined impact: abrupt LATAM import requirements have postponed high-margin shipments despite firm customer orders, Ambernath is carrying about Rs 60 crore of annual expense before its revenue ramp, and increased input costs are passing through with a lag. Management nevertheless retained its Rs 1,000 crore revenue target, citing its order book and scaling products in semi-regulated markets.

The next developments to watch are the scheduled EU audit at Ambernath, progress in customer-specific LATAM import permits over the stated four-to-five-month period, and whether revised customer purchase orders begin reflecting higher raw-material costs within two quarters. Management said it would not guide for the next financial year until the approval outcome and Ambernath's expected sales and research-and-development spending are clearer.